Valneva SE
Valneva SE (VALN): 146 pipeline candidates · 31 upcoming catalysts · ~18 mo cash runway · 403 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.6 months
D/E 2.76 · 0% dilution
Lead: Phase 3
146 candidates
31 upcoming, next in ~13d
N/A
A transparent, data-derived signal for Valneva SEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$507.3M
Cash
$109.7M
Quarterly Burn
$24.5M
Runway
17.6 mo
Revenue
$47.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (146 candidates)
| Drug | Phase |
|---|---|
| 0.9% sodium chloride injection | Phase 4 |
| 052-af | Phase 1 |
| 1- Vasopressor - Mean arterial pressure 56-60 | Phase 3 |
| 15-0 H20 | — |
| 2- Vasopressor - Mean arterial pressure 61-65 | Phase 3 |
| 24-IU oxytocin | Phase 3 |
| 3- Vasopressor - Mean arterial pressure 66-70 | Phase 3 |
| 3M-05-AF | Phase 1 |
| 3M-052-AF | Phase 1 |
| 4- Vasopressor - Mean arterial pressure 71-75 | Phase 3 |
Showing 10 of 146 candidates. Sign up for full pipeline.
Upcoming Catalysts (31)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$10.0M
| Holder | Shares | Value |
|---|---|---|
| novo holdings a/s | 1,057,421 | $6.6M |
| general american investors co inc | 354,361 | $2.2M |
| wells fargo & company/mn | 78,029 | $488K |
| morgan stanley | 46,925 | $293K |
| ironwood investment management llc | 25,135 | $157K |
| old mission capital llc | 13,759 | $86K |
| vsm wealth advisory, llc | 10,000 | $63K |
| rhumbline advisers | 1,793 | $11K |
| gamma investing llc | 1,426 | $9K |
| steigerwald, gordon & koch inc. | 1,250 | $8K |
Showing top 10 of 19 institutional holders of Valneva SE. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Valneva SE's pipeline?
Valneva SE (VALN) has 146 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Valneva SE's lead drug candidate?
Valneva SE's most advanced tracked candidate is 0.9% sodium chloride injection (Phase 4) for Acute Bronchiolitis.
What is Valneva SE's next catalyst?
Valneva SE's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Double-blind, Prospective, Randomized, Placebo-controlled Trial to Assess if Activin Ligand-trap Bio" — expected July 1, 2026.
What is Valneva SE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Valneva SE has approximately 17.6 months of cash runway.
What is Valneva SE's market capitalization?
Valneva SE's market capitalization is approximately $507.3M.
Get the full picture on Valneva SE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.